AVITA Medical (RCEL) 10-Q 7 Nov 24 2024 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 04, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	AVITA MEDICAL, INC.
Entity Central Index Key	0001762303
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Security Exchange Name	NASDAQ
Trading Symbol	RCEL
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Interactive Data Current	Yes
Entity Address, State or Province	CA
Entity Incorporation, State or Country Code	DE
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		26,217,629
Entity File Number	001-39059
Entity Tax Identification Number	85-1021707
Entity Address, Address Line One	28159 Avenue Stanford
Entity Address, Address Line Two	Suite 220
Entity Address, City or Town	Valencia
Entity Address, Postal Zip Code	91355
City Area Code	(661)
Local Phone Number	367-9170

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents	$ 18,639	$ 22,118
Marketable securities	25,766	66,939
Accounts receivable, net	10,288	7,664
BARDA receivables	111	30
Prepaids and other current assets	2,892	1,659
Inventory	6,229	5,596
Total current assets	63,925	104,006
Plant and equipment, net	9,151	1,877
Operating lease right-of-use assets	3,780	2,440
Corporate-owned life insurance ("COLI") asset	3,059	2,475
Intangible assets, net	590	487
Other long-term assets	546	355
Total assets	81,051	111,640
LIABILITIES, NON-QUALIFIED DEFERRED COMPENSATION PLAN SHARE AWARDS AND STOCKHOLDERS' EQUITY
Accounts payable and accrued liabilities	4,187	3,793
Accrued wages and fringe benefits	9,776	7,972
Current non-qualified deferred compensation ("NQDC") liability	1,870	168
Other current liabilities	1,308	1,266
Total current liabilities	17,141	13,199
Long-term debt	42,547	39,812
Non-qualified deferred compensation liability	2,742	3,663
Contract liabilities	332	357
Operating lease liabilities, long term	3,079	1,702
Warrant liability	2,759	3,158
Total liabilities	68,600	61,891
Non-qualified deferred compensation plan share awards	224	693
Commitments and contingencies (Note 11)
Stockholders' equity:
Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 26,217,629 and 25,682,078, shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	3	3
Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2024 and December 31, 2023
Company common stock held by the non-qualified deferred compensation plan	(1,255)	(1,130)
Additional paid-in capital	363,769	350,039
Accumulated other comprehensive loss	(2,065)	(1,887)
Accumulated deficit	(348,225)	(297,969)
Total stockholders' equity	12,227	49,056
Total liabilities, non-qualified deferred compensation plan share awards and stockholders' equity	$ 81,051	$ 111,640

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock par value	$ 0.0001	$ 0.0001
Common stock shares authorized	200,000,000	200,000,000
Common stock shares issued	26,217,629	25,682,078
Common stock shares outstanding	26,217,629	25,682,078
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Sales revenue	$ 19,394,000	$ 13,645,000	$ 45,681,000	$ 35,948,000
Lease revenue	152,000		164,000
Total revenues	19,546,000	13,645,000	45,845,000	35,948,000
Cost of sales	(3,190,000)	(2,113,000)	(6,814,000)	(5,984,000)
Gross profit	16,356,000	11,532,000	39,031,000	29,964,000
BARDA income		212,000		1,369,000
Operating expenses:
Sales and marketing	(15,144,000)	(10,532,000)	(44,086,000)	(27,075,000)
General and administrative	(9,590,000)	(6,124,000)	(26,071,000)	(20,584,000)
Research and development	(5,428,000)	(4,394,000)	(15,510,000)	(14,056,000)
Total operating expenses	(30,162,000)	(21,050,000)	(85,667,000)	(61,715,000)
Operating loss	(13,806,000)	(9,306,000)	(46,636,000)	(30,382,000)
Interest expense	(1,359,000)	(10,000)	(4,063,000)	(21,000)
Other (expense) income, net	(1,068,000)	615,000	478,000	2,141,000
Loss before income taxes	(16,233,000)	(8,701,000)	(50,221,000)	(28,262,000)
Income tax benefit (expense)	28,000	(11,000)	(35,000)	(54,000)
Net loss	$ (16,205,000)	$ (8,712,000)	$ (50,256,000)	$ (28,316,000)
Net loss per common share:
Basic	$ (0.62)	$ (0.34)	$ (1.95)	$ (1.12)
Diluted	$ (0.62)	$ (0.34)	$ (1.95)	$ (1.12)
Weighted-average common shares:
Basic	25,983,929	25,401,754	25,794,690	25,281,920
Diluted	25,983,929	25,401,754	25,794,690	25,281,920

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (16,205)	$ (8,712)	$ (50,256)	$ (28,316)
Other comprehensive income gain/(loss):
Foreign currency translation loss		(47)		(57)
Change in fair value due to credit risk on long-term debt loss	(554)		(116)
Net unrealized gain/(loss) on marketable securities	45	65	(62)	407
Comprehensive loss	$ (16,714)	$ (8,694)	$ (50,434)	$ (27,966)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Company Common Stock Held by the NQDC Plan	Additional Paid-in Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2022	$ 84,740,000	$ 3,000	$ (127,000)	$ 339,825,000	$ 7,627,000	$ (262,588,000)
Beginning balance, shares at Dec. 31, 2022		25,208,436
Net loss	(28,316,000)					(28,316,000)
Stock-based compensation	5,738,000			5,738,000
Vesting of restricted stock units, shares		50,336
Exercise of stock options	942,000			942,000
Exercise of stock options, shares		163,750
Vesting of Company common stock held by the NQDC Plan			(1,401,000)	1,401,000
Vesting of Company common stock held by the NQDC Plan, shares		128,172
Distribution of Company common stock held by the NQDC Plan	522,000		238,000	284,000
Change in redemption value of share awards in NQDC Plan	(998,000)			(998,000)
Net unrealized gain (loss) on marketable securities	407,000				407,000
Foreign currency translation gain/(loss)	(57,000)				(57,000)
Ending Balance at Sep. 30, 2023	62,978,000	$ 3,000	(1,290,000)	347,192,000	7,977,000	(290,904,000)
Ending Balance, shares at Sep. 30, 2023		25,550,694
Beginning Balance at Jun. 30, 2023	68,647,000	$ 3,000	(892,000)	343,769,000	7,959,000	(282,192,000)
Beginning balance, shares at Jun. 30, 2023		25,447,615
Net loss	(8,712,000)					(8,712,000)
Stock-based compensation	2,367,000			2,367,000
Vesting of restricted stock units, shares		45,336
Exercise of stock options	110,000			110,000
Exercise of stock options, shares		17,221
Vesting of Company common stock held by the NQDC Plan			(636,000)	636,000
Vesting of Company common stock held by the NQDC Plan, shares		40,522
Distribution of Company common stock held by the NQDC Plan	522,000		238,000	284,000
Change in redemption value of share awards in NQDC Plan	26,000			26,000
Net unrealized gain (loss) on marketable securities	65,000				65,000
Foreign currency translation gain/(loss)	(47,000)				(47,000)
Ending Balance at Sep. 30, 2023	62,978,000	$ 3,000	(1,290,000)	347,192,000	7,977,000	(290,904,000)
Ending Balance, shares at Sep. 30, 2023		25,550,694
Beginning Balance at Dec. 31, 2023	49,056,000	$ 3,000	(1,130,000)	350,039,000	(1,887,000)	(297,969,000)
Beginning balance, shares at Dec. 31, 2023		25,682,078
Net loss	(50,256,000)					(50,256,000)
Stock-based compensation	10,603,000			10,603,000
Vesting of restricted stock units, shares		94,123
Exercise of stock options	$ 1,701,000			1,701,000
Exercise of stock options, shares	301,524	301,524
ESPP purchase	$ 786,000			786,000
ESPP purchase, Shares		96,253
Distribution/diversification of Company common stock held by the NQDC Plan	321,000		245,000	76,000
Vesting of Company common stock held by the NQDC Plan			(370,000)	370,000
Vesting of Company common stock held by the NQDC Plan, shares		43,651
Change in redemption value of share awards in NQDC Plan	194,000			194,000
Net unrealized gain (loss) on marketable securities	(62,000)				(62,000)
Change in fair value due to credit risk on long-term debt	(116,000)				(116,000)
Ending Balance at Sep. 30, 2024	12,227,000	$ 3,000	(1,255,000)	363,769,000	(2,065,000)	(348,225,000)
Ending Balance, shares at Sep. 30, 2024		26,217,629
Beginning Balance at Jun. 30, 2024	23,915,000	$ 3,000	(1,022,000)	358,510,000	(1,556,000)	(332,020,000)
Beginning balance, shares at Jun. 30, 2024		25,949,906
Net loss	(16,205,000)					(16,205,000)
Stock-based compensation	4,040,000			4,040,000
Vesting of restricted stock units, shares		50,157
Exercise of stock options	1,008,000			1,008,000
Exercise of stock options, shares		183,867
Distribution/diversification of Company common stock held by the NQDC Plan	56,000		58,000	(2,000)
Vesting of Company common stock held by the NQDC Plan			(291,000)	291,000
Vesting of Company common stock held by the NQDC Plan, shares		33,699
Change in redemption value of share awards in NQDC Plan	(78)			(78)
Net unrealized gain (loss) on marketable securities	45,000				45,000
Change in fair value due to credit risk on long-term debt	(554,000)				(554,000)
Ending Balance at Sep. 30, 2024	$ 12,227,000	$ 3,000	$ (1,255,000)	$ 363,769,000	$ (2,065,000)	$ (348,225,000)
Ending Balance, shares at Sep. 30, 2024		26,217,629

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flow from operating activities:
Net loss	$ (50,256,000)	$ (28,316,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of long-term debt	2,619,000
Change in fair value of warrant liability	(399,000)
Depreciation and amortization	717,000	445,000
Stock-based compensation	10,698,000	6,213,000
Non-cash lease expense	633,000	531,000
Loss on fixed asset disposal	25,000	83,000
Investment losses		17,000
Remeasurement and foreign currency transaction gain/(loss)	23,000	(23,000)
Excess and obsolete inventory related charges	408,000	149,000
BARDA deferred costs		(147,000)
Contract cost amortization		255,000
Provision for credit losses	33,000	113,000
Amortization of premium of marketable securities	(1,479,000)	(794,000)
Non-cash changes in the fair value of NQDC plan	36,000	899,000
Changes in operating assets and liabilities:
Trade and other receivables	(2,656,000)	(2,473,000)
BARDA receivables	(81,000)	697,000
Prepaids and other current assets	(1,233,000)	(2,057,000)
Inventory	(1,041,000)	(2,405,000)
Operating lease liability	(667,000)	(571,000)
Corporate-owned life insurance ("COLI") asset	(271,000)	(643,000)
Other long-term assets	(192,000)	(114,000)
Accounts payable and accrued expenses	(65,000)	(70,000)
Accrued wages and fringe benefits	1,804,000	524,000
Current non-qualified deferred compensation liability	1,625,000	(651,000)
Other current liabilities	112,000	345,000
Non-qualified deferred compensation plan liability	(1,242,000)	1,174,000
Contract liabilities	(25,000)	(333,000)
Net cash used in operations	(40,858,000)	(27,148,000)
Cash flows from investing activities:
Purchase of marketable securities	(18,609,000)	(7,633,000)
Sale of marketable securities		2,372,000
Maturities of marketable securities	61,200,000	65,289,000
Purchase of plant and equipment	(7,559,000)	(1,085,000)
Patent filing fees	(140,000)	(32,000)
Net cash provided by investing activities	34,892,000	58,911,000
Cash flow from financing activities:
Proceeds from exercise of stock options	1,701,000	942,000
Employee stock purchase plan ("ESPP") purchases	786,000
Net cash provided by financing activities	2,487,000	942,000
Effect of foreign exchange rate on cash and cash equivalents		(15,000)
Net increase/(decrease) in cash and cash equivalents	(3,479,000)	32,690,000
Cash and cash equivalents beginning of the period	22,118,000	18,164,000
Cash and cash equivalents end of the period	18,639,000	50,854,000
Supplemental Disclosure of Cash Flow Information:
Income taxes paid during the period	21,000	44,000
Interest paid during the period	4,062,000	21,000
Non-cash investing and financing activities:
Plant and equipment purchases not yet paid	407,000	$ 114,000
Right-of-use-asset obtained in exchange for lease liabilities	$ 2,026,000

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (16,205)	$ (8,712)	$ (50,256)	$ (28,316)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

The Company

The Company	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company Nature of the Business AVITA Medical, Inc. (collectively with its subsidiaries, “AVITA Medical”, “we”, “our”, “us”, or the “Company”) is a commercial-stage regenerative medicine company transforming the standard of care in wound management and skin restoration with innovative devices. At the forefront of the Company's portfolio is its patented and proprietary RECELL ® technology (“RECELL”). RECELL harnesses the regenerative properties of a patient’s own skin to create an autologous skin cell suspension, Spray-On Skin ™ Cells, delivering a transformative solution at the point of care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. The Company also holds the right to market, sell, and distribute PermeaDerm ® , a biosynthetic wound matrix, in the United States under the terms of an exclusive multi-year distribution agreement with Stedical Scientific, Inc. (“Stedical”). The Company also entered into an exclusive multi-year development and distribution agreement with Regenity Biosciences (“Regenity”). Following 510(k) approval, Regenity will manufacture and supply Cohealyx ™ , an AVITA-medical branded collagen-based dermal matrix. Under the agreement, the Company will hold the exclusive rights to market, sell, and distribute Cohealyx in the U.S., with potential expansion into the European Union, as well as in Australia and Japan. The single-use RECELL Autologous Cell Harvesting Device (“RECELL Ease-of-Use” or “RECELL EOU”) is approved by the U.S. Food and Drug Administration (the “FDA”) for the treatment of thermal burn wounds and full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. The Company's next-generation device, RECELL GO ™ Autologous Cell Harvesting Device (“RECELL GO”), is FDA-approved to treat thermal burn wounds and full-thickness skin defects. RECELL GO introduces enhanced features that streamline the preparation of Spray-On Skin Cells and improves workflow efficiency in the operating room. It consists of two components: a multi-use, AC-powered RECELL GO Processing Device (the “RPD”) and a RECELL GO Preparation Kit (the “RPK”). The RPK contains the single-use RECELL GO Cartridge, disaggregation head, RECELL Enzyme ™ , and other components. The RPD provides the control for the RPK, manages the pressure applied to disaggregate the donor skin cells, and precisely regulates the incubation times of the RECELL Enzyme and solutions to optimize cell yield and promote cell viability.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the Consolidated Financial Statements reflect all adjustments of a normal and recurring nature that are considered necessary for a fair presentation of the results for the interim periods presented. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year-ended December 31, 2023 filed with the SEC on February 22, 2024 and the Australian Securities Exchange (“ASX”) on February 23, 2024 (the “2023 Annual Report”). Except for revenue recognition, related to the RECELL GO system, as described below, there have been no changes to the Company’s significant accounting policies as described in the 2023 Annual Report that have had a material impact on the Company’s Consolidated Financial Statements. See the summary of the Company’s significant accounting policies set forth in the notes to its Consolidated Financial Statements included in the 2023 Annual Report. Principles of Consolidation The accompanying Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07, S egment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (“CODM”) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU on its Consolidated Financial Statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments affected by this ASU require (i) enhanced disclosures in connection with an entity's effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. These amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of adopting this ASU on its Consolidated Financial Statements and disclosures. Use of Estimates The preparation of the accompanying Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts (including the stand-alone selling price (“SSP” ) for the RPD, allowance for credit losses, reserves for inventory excess and obsolescence, carrying value of long-lived assets, the useful lives of long-lived assets, accounting for marketable securities, income taxes, fair value of debt, fair value of warrants and stock-based compensation) and related disclosures. Estimates have been prepared based on the current and available information. However, actual results could differ from estimated amounts. Foreign Currency Translation and Foreign Currency Transactions The financial position and results of operations of the Company’s operating non-U.S. subsidiaries are generally determined using the respective local currency as the functional currency of that subsidiary. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each period end. Income statement accounts are translated at the average rate of exchange prevailing during the period. Adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive loss in the Consolidated Balance Sheets. The Company’s non-operating subsidiaries that use the U.S. Dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period and nonmonetary assets and liabilities at historical rates. Gains and losses resulting from these remeasurements are included in earnings in the Consolidated Statement of Operations. Gains and losses for remeasurement were minimal during the three-months and nine-months ended September 30, 2024 and 2023. The Company records certain revenues and operating expenses in foreign currencies. These revenues and expenses are translated into U.S. Dollars based on the average exchange rate for the reporting period. Assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate in effect as of the balance sheet date. For the three and nine-months ended September 30, 2024, the Company incurred approximately $ 11,000 and $ 23,000 in losses included in Net loss in the Consolidated Statement of Operations, respectively. For the three and nine-months ended September 30, 2023, t he Company incurred approximately $ 26,000 and $ 23,000 in gains included in Net loss in the Consolidated Statement of Operations, respectively. Cash and Cash Equivalents Cash and cash equivalents consist of cash held at deposit institutions and cash equivalents. Cash equivalents consist primarily of money market funds. Cash equivalents also include short-term highly liquid investments with original maturities of three months or less from the date of purchase. The Company holds cash at deposit institutions in the amount of $ 5.3 million and $ 10.7 million as of September 30, 2024 and December 31, 2023, respectively. The Company does no t have cash on deposit denominated in foreign currency in foreign institutions as of September 30, 2024. As of December 31, 2023, the Company had $ 69,000 of cash on deposit denominated in foreign currencies in foreign institutions. As of September 30, 2024 and December 31, 2023, the Company held cash equivalents in the amounts of $ 13.3 million and $ 11.4 million , respectively. Rabbi Trust During April 2022, the Company established a rabbi trust to hold the assets of the NQDC Plan. The rabbi trust holds the COLI asset and the Common stock from deferred restricted stock unit awards that have vested. The NQDC Plan permits diversification of fully vested shares into other equity securities subject to a six-month-and-one-day holding period. In accordance with ASR 268 , Redeemable Preferred Stock , and ASC 718 , Compensation — Stock Compensation , prior to vesting, the deferred share awards are classified as an equity instrument and changes in fair value of the amount owed to the participant are not recognized. The redemption amounts of the deferred awards are based on the vested percentage and are recorded outside of permanent equity as Non-qualified deferred compensation share awards on the Consolidated Balance Sheets. Common stock held in the rabbi trust is classified in a manner similar to treasury stock and presented separately on the Consolidated Balance Sheets as Company common stock held by the NQDC plan. As of September 30, 2024 and December 31, 2023, a total of 91,026 and 81,052 shares awards have been deferred, respectively. Vested shares are converted to Common stock and are reclassified to permanent equity. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, and debt and other liabilities. As of September 30, 2024 and December 31, 2023, substantially all the Company’s cash and cash equivalents were deposited in accounts at financial institutions, and those deposited amounts exceed federally insured limits and are subject to the risk of bank failure. As of September 30, 2024 and December 31, 2023, no single commercial customer accounted for more than 10 % of net accounts receivable or more than 10 % of revenues for the three-months and nine-months ended September 30, 2024 and 2023. Revenue Recognition The Company generates revenues primarily from: • The sale of RECELL EOU, RPK, and PermeaDerm products to hospitals, other treatment centers, and distributors. • Maintenance fee received from BARDA to ensure first right of access to our inventory. In the prior year, the Company recorded service revenue for the emergency preparedness services provided to BARDA. • Lease revenue for the RPD. The Company’s sale of the RECELL EOU and PermeaDerm products are accounted for under ASC 606, Revenue from contracts with customers (“ASC 606”). Revenue for the RECELL GO system is disaggregated between two accounting standards: (1) ASC 606 for the RPK and (2) ASC 842, Leases (“ASC 842”) for the RPD. Revenues from BARDA are accounted for under ASC 606, and are included in Sales revenues within the Consolidated Statements of Operations. To determine revenue recognition for contracts that are within the scope of ASC 606, the Company performs the following five steps: 1. Identify the contract with a customer 2. Identify the performance obligations 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations 5. Recognize revenue when/as a performance obligation(s) is(are) satisfied In order for an arrangement to be considered a contract, it must be probable that the Company will collect the consideration to which it is entitled for goods or services to be transferred. The Company then assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. The Company determines the transaction price based on the amount of consideration the Company expects to receive for providing the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. When accounting for a contract that contains multiple performance obligations, the Company must develop judgmental assumptions to determine the estimated SSP for each performance obligation identified in the contract. We utilize the observable SSP when available, which represents the price charged for the promised product or service when sold separately. When the SSP for our products or services are not directly observable, we determine the SSP using relevant information available and apply suitable estimation methods including, but not limited to, the cost-plus margin approach. The Company then allocates the transaction price to each performance obligation based on the relative SSP and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. Most of the Company’s contracts have a single performance obligation. As such, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. Revenue is recognized net of volume discounts (variable consideration). For the Company’s contracts that have an original duration of one year or less, since contract inception and customer payment occur within the same period the Company does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract acquisition costs such as commissions and shipping and handling expenses as incurred. Revenue recognition for contracts that are within the scope of ASC 606 and ASC 842 The Company enters into contracts with customers where it receives consideration for the RPK and does not receive additional consideration for the RPD. As a result, judgment and analysis are required to determine the appropriate accounting, including: (i) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (ii) the amount of the total consideration, as well as variable consideration, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. For these contracts the Company considers the guidance under ASC 842 to determine if furnishing the RPD to the customer during the period of use establishes an embedded lease. To determine if the contract contains a lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company. As the contract conveys the right to control the use of an identified asset for a period of time, the contract was determined to contain a lease. The Company then evaluated the lease classification based on the below: • Pursuant to ASC 842-30, the Company will classify a lease as a sales-type lease if: (i) the lease transfers ownership of the underlying asset to the lessee by the end of the lease term, (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise, (iii) the lease term is for the major part of the remaining economic life of the underlying asset, (iv) the present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments equals or exceeds substantially all (90% or more) of the fair value of the underlying asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. • Pursuant to ASC 842-30, when none of the sales-type lease classification criteria are met, a lessor would classify the lease as a direct financing lease when both of the following criteria are met: (i) the present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments and/or any other third party unrelated to the lessor equals or exceeds substantially all (90% or more) of the fair value of the underlying asset and (ii) it is probable that the lessor will collect the lease payments plus any amount necessary to satisfy a residual value guarantee. • Pursuant to ASC 842-30, a lessor would classify a lease as an operating lease when none of the sales-type or direct financing lease classification criteria are met. Further, per ASC 842, a lessor is required to classify a lease with variable lease payments that do not depend on an index or rate as an operating lease at lease commencement if the lease would have been classified as a sales-type lease or a direct financing lease in accordance with the classification criteria of ASC 842 and the lessor would have otherwise recognized a loss at the lease commencement date. In determining whether the lease components are related to a sales-type lease or an operating lease, the Company evaluates if the lease transfers ownership at the end of the lease term, purchase options, the lease term in relation to the economic life of the asset, if the lease payments exceed the fair value of the asset, and if the asset is of a specialized nature. The Company also evaluates if the lease results in a loss at the lease commencement date. As the lease term is for the major part of the economic life, the lease meets the classification criteria for sales-type lease. However, t o determine if the contract results in a loss at the lease commencement date the Company evaluated the consideration in the contract. The consideration at lease commencement does not contain fixed payments, purchase options, penalty payments or residual value guarantees. The variable consideration is related to the sale of the RPK. As the variable lease payments are not dependent on an index or rate, the variable consideration is excluded from consideration at contract inception resulting in a loss at lease commencement. As such, the Company classifies the lease as an operating lease. The contracts contain a lease component, the RPD, and a non-lease component, the RPK. The lease component will be accounted for under the ASC 842 and the non-lease component will be accounted for under ASC 606, as described above. In accordance with ASC 842, the consideration in the contract will be allocated to each separate lease component and non-lease component of the contract. The consideration is allocated to these lease and non-lease components based on the SSP (as described above for contracts within the scope of ASC 606). In accordance with ASC 842, variable lease payments will be recognized once the sale of the RPK occurs and control has transferred to the customer. Consideration will be allocated to the RPD and RPK based on the SSP. Consideration related to the RPD will be recognized as Lease revenue and consideration related to the RPK will be recognized as Sales revenues in accordance with guidance in ASC 606, as described above, upon transfer of control of the RPK, which generally occurs at the time the product is shipped or delivered depending on the customer's shipping terms. Assets in our lease program are reported in Plant and equipment, net on our Consolidated Balance Sheets and are depreciated over the useful life of the RPD device's 200 uses, as indicated in the Instructions for Use that were approved by the FDA, and expensed as Costs of goods sold in the Consolidated Statements of Operations. The RPD depreciation has a direct relationship to the number of RPK units sold. Based on customer usage, each purchase of an RPK unit results in a 1/200 depreciation to the RPD .

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2024
Debt Securities, Available-for-Sale [Abstract]
Marketable Securities	3. Marketable Securities The following table summarizes the amortized cost and estimated fair values of securities available-for-sale: As of September 30, 2024 Amortized Gross Gross Carrying (in thousands) Cash equivalents: Money market funds $ 13,357 $ - $ - $ 13,357 Total cash equivalents $ 13,357 $ - $ - $ 13,357 Current marketable securities: U.S. Treasury securities $ 25,732 $ 34 $ - $ 25,766 Total current marketable securities $ 25,732 $ 34 $ - $ 25,766 As of December 31, 2023 Amortized Gross Gross Carrying (in thousands) Cash equivalents: Money market funds $ 8,427 $ - $ - $ 8,427 U.S. Treasury securities 2,992 - - 2,992 Total cash equivalents $ 11,419 $ - $ - $ 11,419 Current marketable securities: U.S. Treasury securities $ 65,145 $ 100 $ ( 3 ) $ 65,242 U.S. Government agency obligations 1,699 - ( 2 ) 1,697 Total current marketable securities $ 66,844 $ 100 $ ( 5 ) $ 66,939 The maturities of our available-for-sale securities are summarized in the following table using contractual maturities. Actual maturities may differ from contractual maturities due to obligations that are called or prepaid. As of September 30, 2024 As of December 31, 2023 (in thousands) Amortized Carrying Amortized Carrying Due in one year or less $ 25,732 $ 25,766 $ 66,844 $ 66,939 Unrealized gains and losses, net of any related tax effects for available-for-sale securities are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders' equity until realized. Realized gains and losses on marketable securities are included in Other income, net, in the accompanying Consolidated Statements of Operations. The Company had net unrealized gains of $ 34,000 and $ 95,000 as of September 30, 2024 and December 31, 2023, respectively. The Company did no t have sales of investments during the three-months and nine-months ended September 30, 2024 and 2023 that resulted in realized gains or losses. As of September 30, 2024, and December 31, 2023, the Company did no t recognize credit losses. The Company has accrued interest income receivable of $ 154,000 and $ 227,000 as of September 30, 2024, and December 31, 2023, respectively, in Prepaids and other current assets in the Consolidated Balance Sheets.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements ASC 820, Fair Value Measurement , the authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels: Level 1: Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date. Level 2: Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Inputs are unobservable inputs for the asset or liability. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy: As of September 30, 2024 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 13,357 $ - $ - $ 13,357 Total cash equivalents $ 13,357 $ - $ - $ 13,357 Current marketable securities: U.S. Treasury securities $ - $ 25,766 $ - $ 25,766 Total current marketable securities $ - $ 25,766 $ - $ 25,766 Total marketable securities and cash equivalents $ 13,357 $ 25,766 $ - $ 39,123 Financial liabilities: Long-term debt $ - $ - $ 42,547 $ 42,547 Warrant liability - - 2,759 $ 2,759 Non-qualified deferred compensation plan liability - 4,612 - $ 4,612 Total financial liabilities $ - $ 4,612 $ 45,306 $ 49,918 Financial assets: Corporate-owned life insurance policies $ - $ 3,059 $ - $ 3,059 Total financial assets $ - $ 3,059 $ - $ 3,059 As of December 31, 2023 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 8,427 $ - $ - $ 8,427 U.S. Treasury securities - 2,992 - 2,992 Total cash equivalents $ 8,427 $ 2,992 $ - $ 11,419 Current marketable securities: U.S. Treasury securities $ - $ 65,242 $ - $ 65,242 U.S. Government agency obligations - 1,697 - 1,697 Total current marketable securities $ - $ 66,939 $ - $ 66,939 Total marketable securities and cash equivalents $ 8,427 $ 69,931 $ - $ 78,358 Financial liabilities: Long-term debt $ - $ - $ 39,812 $ 39,812 Warrant liability - - 3,158 3,158 Non-qualified deferred compensation plan liability - 3,831 - $ 3,831 Total financial liabilities $ - $ 3,831 $ 42,970 $ 46,801 Financial assets: Corporate-owned life insurance policies $ - $ 2,475 $ - $ 2,475 Total financial assets $ - $ 2,475 $ - $ 2,475 The following table presents the summary of changes in the fair value of our Level 3 financial instruments: As of September 30, 2024 As of December 31, 2023 (in thousands) Long-term debt Warrant liability Long-term debt Warrant liability Balance beginning of period $ 39,812 $ 3,158 $ - $ - Fair value on issuance date 37,575 2,425 Change in fair value in earnings 2,619 ( 399 ) 1,616 733 Change in fair value in other comprehensive loss 116 - 621 - Balance end of period, at fair value $ 42,547 $ 2,759 $ 39,812 $ 3,158 The Company’s Level 1 assets include money market instruments and are valued based upon observable market prices. Level 2 assets consist of U.S Treasury securities and U.S. Government Agency obligations. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. The corporate-owned life insurance contracts are recorded at cash surrender value, which approximates the fair value and is categorized as Level 2. Non-qualified deferred compensation plan liability is measured at fair value based on quoted prices of identical instruments to the investment vehicles selected by the participants and it is recorded as Level 2. There were no transfers between fair value measurement levels during the periods ended September 30, 2024 and December 31, 2023. Long-term debt The fair value of the debt was determined using a Monte Carlo Simulation (“MCS”) in order to predict the probability of different outcomes. The valuation was performed based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the debt is recorded in the Consolidated Balance Sheets. The fair value is estimated by the Company each reporting period and the change in the fair value is recorded in both earnings and other comprehensive income depending on the instrument's inherent credit risk and market risk related to the debt valuation. As the debt is subject to net revenue requirements, the valuation of the debt was determined using MCS. The underlying metric to be simulated is the projected Trailing Twelve Month (“TTM”) revenues at each quarter end through the maturity date of October 18, 2028. Based on the simulated metric, the different levels of simulated TTM revenues may trigger different discounted cash flow scenarios in which the TTM revenues are lower than the targeted revenues per the Credit Agreement or the TTM revenues are equal to or higher than the targeted revenues per the Credit Agreement, as discussed in Note 6 of our Consolidated Financial Statements. MCS performs 100,000 iterations of various simulated revenues to determine the fair value of the debt. The below assumptions were used in the MCS: September 30, 2024 December 31, 2023 Risk-free interest rate 3.53 % 3.81 % Revenue volatility 64.00 % 64.00 % Revenue discount rate 14.41 % 16.58 % Warrant Liability The fair value of the warrant liability is recognized in connection with the Credit Agreement. The fair value of the warrant liability was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the warrant liability, which is reported within Warrant liability on the Consolidated Balance Sheets, is estimated by the Company based on the Black-Scholes option pricing model with the follow ing key inputs: September 30, 2024 December 31, 2023 Price of common stock $ 10.72 $ 13.72 Expected term 9.05 years 9.81 years Expected volatility 51.47 % 31.07 % Exercise price $ 10.9847 $ 10.9847 Risk-free interest rate 3.73 % 3.84 % Expected dividends 0.00 % 0.00 %

Revenues

Revenues	9 Months Ended
	Sep. 30, 2024
Revenue, Performance Obligation [Abstract]
Revenues	5. Revenues The Company generates revenues primarily from: • The sale of RECELL Ease of Use (“EOU”), RECELL GO RPK, and PermeaDerm products to hospitals, other treatment centers, and distributors. • Maintenance fee received from BARDA in exchange for first right of access to our inventory. In the prior year, the Company recorded service revenues for the emergency preparedness services provided to BARDA. • Lease revenue for the RECELL GO RPD. The Company’s sale of the EOU and PermeaDerm products are accounted for under ASC 606, as discussed in Note 2 of our Consolidated Financial Statements. Revenue for the RECELL GO device is disaggregated between two accounting standards: (1) ASC 606 for the RPK and (2) ASC 842 for the RPD. RECELL GO The RECELL GO device consists of a single-use RPK and a durable AC powered device, RPD. The Company enters into contracts with customers where it receives consideration for the single-use RPK and does not receive additional consideration for the RPD. The consideration in the contract is allocated based on the SSP. Upon sale of the RPK the consideration is allocated to the lease and non-lease components. Consideration received for the RPK is recorded in Sales revenues in the Consolidated Statement of Operations and consideration for the lease is recorded in Lease revenue in the Consolidated Statement of Operations. During the three and nine-months ended September 30, 2024, the Company recorded approxima tely $ 7.6 million and $ 8.2 million in Sales revenue related to the RPK and $ 152,000 and $ 164,000 in Lease revenue related to the RPD in the Consolidated Statement of Operations, respectively. Distributor Transactions For international markets, the Company exclusively partners with third-party distributors (currently, COSMOTEC in Japan, and PolyMedics Innovation GmbH, in Germany). Revenue recognition occurs when the distributors obtain control of the product. The terms of sales transactions through distributors are generally consistent with the terms of direct sales to customers and do not contain return rights. These transactions are accounted for in accordance with the Company’s revenue recognition policy described in Note 2, Summary of Significant Accounting Policies in our Consolidated Financial Statements. PermeaDerm Sales As provided in the Distribution Agreement with Stedical, the Company’s gross margin from the sale of PermeaDerm is 50 % of the average sales price (“ASP”). The Company and Stedical share the gross revenue from the sale of the products evenly at 50 % of ASP. The Company recognizes revenue when the customer obtains control of promised goods, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. Remaining Performance Obligations Contract liabilities are calculated as the dollar value of the remaining performance obligations on executed contracts and primarily relate to COSMOTEC and other customers. The estimated revenue expected to be recognized in the future once the performance obligation is satisfied under the Company’s existing customer agreements is $ 365,000 and $ 390,000 as of September 30, 2024 and December 31, 2023, respectively. These amounts are classified between current and long-term in Other current liabilities and Contract liabilities in the Consolidated Balance Sheets. Contract Assets and Contract Liabilities Contract assets include amounts related to the Company’s contractual right to consideration for both completed and partially completed performance for which the Company does not have the right to payment. As of September 30, 2024 and December 31, 2023, the Company does no t have any contract assets. Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. Contract liability balance primarily relates to unsatisfied performance obligation with COSMOTEC of $ 365,000 and $ 390,000 as of September 30, 2024 and December 31, 2023, respectively. This balance is classified between current and long-term. As of September 30, 2024 and December 31, 2023, a total of $ 33,000 and $ 33,000 , respectively, was included in Other current liabilities and $ 332,000 and $ 357,000 , respectively, in Contract liabilities in the Consolidated Balance Sheets. The Company recognized approximately $ 8,000 and $ 25,000 of revenue from COSMOTEC for amounts included in the beginning balance of Contract liabilities for the three-months and nine-months ended September 30, 2024 and 2023, respectively. Disaggregated Revenue The Company disaggregates revenue from contracts with customers into geographical regions, by customer type and by product. As noted in the segment footnote, the Company’s business consists of one reporting segment. A reconciliation of revenue by geographical region, customer type and product is provided in Note 10 of our Consolidated Financial Statements.

Long-term Debt

Long-term Debt	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Long-term Debt	6. Long-term debt On October 18, 2023 (the “Closing Date”) the Company entered into a credit agreement, by and between the Company, as borrower, and an affiliate of OrbiMed Advisors, LLC (the “Lender”) as the lender and administrative agent (the “Credit Agreement”). The Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $ 90.0 million, of which (i) $ 40.0 million was made available on the Closing Date (the “Initial Commitment Amount”), (ii) $ 25.0 million is available, at the Company’s discretion, on or prior to December 31, 2024, subject to certain net revenue requirements, and (iii) $ 25.0 million is available, at the Company’s discretion, on or prior to June 30, 2025, subject to certain net revenue requirements (the “Loan Facility”). The maturity date of the Credit Agreement is October 18, 2028 (the “Maturity Date”). On the Closing Date, the Company closed on the Initial Commitment Amount, less certain fees and expenses payable to or on behalf of the Lender. The Company received net proceeds of $ 38.8 million upon closing after deducting the Lender's transaction costs in connection with the Loan Facility. For information regarding an amendment to the Credit Agreement, refer to Note 16 of our Consolidated Financial Statements. All obligations under the Credit Agreement are guaranteed by all of the Company’s wholly owned subsidiaries (subject to certain exceptions) and secured by substantially all of the Company's and each guarantor's assets. The loan will be due in full on the Maturity Date unless the Company elects to repay the principal amount at any time prior to the Maturity Date. Upon prepayment, the Company will owe the applicable repayment premium and exit fee of 3 % on the principal amount of the loans. The repayment premium varies between 0.0 % - 3.0 %, depending on certain conditions that are defined in the Credit Agreement. The repayment premium incorporates the make-whole amount. The make-whole amount represents the remaining scheduled interest payments on the Loan Facility during the period commencing on the prepayment date through the 24-month anniversary of the Closing Date. The Credit Agreement further states that the Company will be required to repay the principal amount of the Loan Facility if the Company does not achieve certain net revenue thresholds. If, for any quarter until the maturity date, the Company’s net revenue does not equal or exceed the applicable trailing 12-month amount as set forth in the Credit Agreement, then the Company shall repay in equal quarterly installments equal to 5.0 % of the outstanding principal amount of the Loan Facility on the date the net revenue amount was not satisfied, together with a repayment premium and exit fee. The Company shall repay amounts outstanding in full immediately upon an acceleration as a result of an event of default as set forth in the Credit Agreement, together with a repayment premium and other fees. As of September 30, 2024, the Company has no t made any repayments on the outstanding debt balance. During the term of the Credit Agreement, interest payable in cash by the Company shall accrue on any outstanding debt at a rate per annum equal to the greater of (x) the SOFR rate for such period and (y) 4.00 % plus, in either case, 8.00 %. As of September 30, 2024, the interest rate was 13.20 %. During an event of default, any outstanding amount will bear interest at a rate of 4.00 % in excess of the otherwise applicable rate of interest. The Company will pay certain fees with respect to the Credit Agreement, including an upfront fee, an unused fee on the undrawn portion of the Loan Facility, an administration fee, a repayment premium and an exit fee, as well as certain other fees and expenses of the Lender. The unused fee accrues at 0.5 % of the undrawn balance and it is recorded as an asset in the Consolidated Balance Sheets. The Credit Agreement contains certain customary events of default, including with respect to nonpayment of principal, interest, fees or other amounts; material inaccuracy of a representation or warranty; failure to perform or observe covenants; material defaults on other indebtedness; bankruptcy and insolvency events; material monetary judgments; loss of certain key permits, persons and contracts; material adverse effects; certain regulatory matters; and any change of control. As of September 30, 2024, the Company was in compliance with all financial covenants in the Credit Agreement. Each of the Credit Agreement and the Pledge and Security Agreement entered into by the Company, the guarantors and the Lender on October 18, 2023 (the “Pledge and Security Agreement”) contains a number of customary representations, warranties and covenants that, among other things, will limit or restrict the ability of the Company and its subsidiaries to (subject to certain qualifications and exceptions): create liens and encumbrances; incur additional indebtedness; merge, dissolve, liquidate or consolidate; make acquisitions, investments, advances or loans; dispose of or transfer assets; pay dividends or make other payments in respect of their capital stock; amend certain material documents; redeem or repurchase certain debt; engage in certain transactions with affiliates; and enter into certain restrictive agreements. In addition, the Company and the guarantors will be required to maintain at least $ 10.0 million of unrestricted cash and cash equivalents. On the Closing Date, the Company issued to an affiliate of the Lender a warrant (the “Warrant”) to purchase up to 409,661 shares of the Company’s Common Stock, par value $ 0.0001 per share, at an exercise price of $ 10.9847 per share, with a term of 10 years from the issuance date. The Warrant contains customary share adjustment provisions, as well as weighted average price protection in certain circumstances. As permitted under ASC 825, Financial Instruments , the Company elected the fair value option to record the long-term debt and warrant with changes in fair value recorded in the Consolidated Statements of Operations in Other income, net. Changes related to instrument-specific credit risk are revalued by comparing the amount of the total change in fair value of the long-term debt to the amount of change in fair value that would have occurred if the Company’s credit sp read had not changed between the reporting periods, and is recorded in Accumulated other comprehensive loss in the Consolidated Balance Sheet. The difference between the fair value of the long-term debt and the unpaid principal balance of $ 40.0 million is an additional liability of $ 2.5 million and reduction to the liability of $ 188,000 as of September 30, 2024 and December 31, 2023, respectively. For changes in fair value, refer to Note 4 of our Consolidated Financial Statements.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Inventory	7. Inventory The composition of the inventory is as follows (in thousands): As of September 30, 2024 December 31, 2023 Raw materials $ 2,731 $ 3,683 Work in process 427 878 Finished goods 3,071 1,035 Total inventory $ 6,229 $ 5,596 The Company values its inventories to reflect the lower of cost or net realizable value. Charges for estimated excess and obsolescence are recorded in Cost of sales in the Consolidated Statements of Operations and were $ 173,000 and $ 81,000 for the three-months ended September 30, 2024 and 2023, respectively, and $ 408,000 and $ 149,000 for the nine-months ended September 30, 2024 and 2023, respectively. The inventory balance as of September 30, 2024, includes inventory purchased from Stedical for the sales of PermeaDerm.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	8. Intangible Assets The composition of intangible assets, net is as follows (in thousands): As of September 30, 2024 As of December 31, 2023 Weighted Gross Accumulated Net Gross Accumulated Net Patent 1 - $ - $ - $ - $ 17 $ ( 17 ) $ - Patent 2 12 136 ( 43 ) 93 141 ( 39 ) 102 Patent 3 14 234 ( 65 ) 169 206 ( 54 ) 152 Patent 5 18 108 ( 15 ) 93 99 ( 11 ) 88 Patent 6 16 62 ( 9 ) 53 56 ( 6 ) 50 Patent 7 - - - - 2 - 2 Patent 8 18 42 ( 3 ) 39 29 ( 1 ) 28 Patent 9 2 117 ( 28 ) 89 3 - 3 Patent 10 - - - - 3 - 3 Patent 11 - - - - 6 ( 1 ) 5 Trademarks Indefinite 54 - 54 54 - 54 Total intangible assets $ 753 $ ( 163 ) $ 590 $ 616 $ ( 129 ) $ 487 For the three-months ended September 30, 2024 and 2023, the Company did not identify any events or changes in circumstances that indicated that the carrying value of its intangibles may not be recoverable. As such, there was no impairment of intangible assets recognized for the three-months ended September 30, 2024 and 2023. For the nine-months ended September 30, 2024 and 2023, the Company recorded a loss on disposal for patents of approximately $ 16,000 and $ 4,000 , respectively, in General and administrative expenses in the Consolidated Statement of Operations. Amortization expense of intangibles included in the Consolidated Statements of Operations was $ 23,000 and $ 9,000 for the three-months ended September 30, 2024 and 2023, respectively, and $ 56,000 and $ 26,000 for the nine-months ended September 30, 2024 and 2023, respectively. The Company expects the future amortization of amortizable intangible assets held at September 30, 2024 to be as follows (in thousands): Estimated Amortization Expense Remainder of 2024 $ 47 2025 93 2026 49 2027 40 2028 40 Thereafter 267 Total $ 536

Plant and Equipment

Plant and Equipment	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Plant and Equipment	9. Plant and Equipment The composition of plant and equipment, net is as follows (in thousands): As of Useful Lives September 30, 2024 December 31, 2023 Computer equipment 3 - 5 years $ 1,632 $ 984 Computer software 3 years 836 840 Construction in progress (“CIP”) 90 87 Furniture and fixtures 7 years 1,112 824 Laboratory and other equipment 3 - 5 years 954 769 Leasehold improvements Lesser of life or lease term 4,196 367 RECELL moulds 5 years 462 438 RECELL GO RPD CIP 1,531 - RECELL GO RPD 318 - Operating lease assets - RPD 200 uses 1,071 - Less: accumulated amortization and depreciation ( 3,051 ) ( 2,432 ) Total plant and equipment, net $ 9,151 $ 1,877 Construction in progress consists primarily of leasehold improvements for the renovations to the Ventura production facility, and RECELL GO RPD CIP consists of materials for the manufacture of the RPDs. RPDs have a useful life of 200 uses and are being amortized based on customer usage as determined by orders placed for the sales of RPK units. RECELL GO RPD represents assets available to be leased by customers and are not depreciated until leased. Depreciation expense related to plant and equipment was $ 288,000 and $ 156,000 for the three-months ended September 30, 2024 and 2023, respectively, and $ 661,000 and $ 419,000 for the nine-months ended September 30, 2024 and 2023, respectively. No impairment was recorded for the three-months ended September 30, 2024. During the nine-months ended September 30, 2024, the Company recorded a loss on disposal of fixed ass ets for a pproximately $ 5,000 . During the three-months and nine-months ended September 30, 2023, the Company recorded a loss on disposal of fixed assets for approximately of $ 80,000 and $ 83,000 , respectively. Amounts are recorded in General and administrative expenses in the Consolidated Statement of Operations. Lessor Arrangements As discussed in Note 5 o f our Consolidated Financial Statements, the contracts for the RECELL GO device include an operating lease for the customer’s right to use the RPD. The lease arrangement does not contain fixed consideration. Variable lease payments are not included in consideration at lease inception. The variable consideration related to the lease is allocated based on the SSP and is recognized when control of the RPK is transferred to the customer. The table below summarizes the Company's Lease revenue as presented in the Consolidated Statement of Operations for the three and nine-months ended September 30, 2024 and 2023. Three-Months Ended Nine-Months Ended (in thousands) September 30, 2024 September 30, 2024 Variable lease revenue $ 152 164 Assets held for lease and included in Plant and equipment consisted of the following (in thousands): As of September 30, 2024 Rental RPD assets $ 1,071 Accumulated depreciation ( 24 ) Net rental RPD assets $ 1,047

Reporting Segment and Geographi

Reporting Segment and Geographic Information	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Reporting Segment and Geographic Information	10. Reporting Segment and Geographic Information The Company views its operations and manages its business in one reporting segment. Long-lived assets are primarily located in the United States as of September 30, 2024, and December 31, 2023. Revenue by region for the three-months and nine-months ended September 30, 2024 and 2023 were as follows (in thousands): Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Revenue by region: United States $ 19,048 $ 12,961 $ 44,162 $ 33,379 Japan 388 581 1,237 2,309 European Union - - 155 - Australia 54 61 132 156 United Kingdom 56 42 159 104 Total $ 19,546 $ 13,645 $ 45,845 $ 35,948 Revenue by customer type for the three-months and nine-months ended September 30, 2024 and 2023 were as follows (in thousands): Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Revenue by customer type: Commercial sales $ 19,482 $ 13,547 $ 45,681 $ 35,673 Deferred commercial revenue recognized 8 8 25 25 BARDA revenue for right of first access 56 90 139 250 Total $ 19,546 $ 13,645 $ 45,845 $ 35,948 Commercial revenue by product for the three-months and nine-months ended September 30, 2024 and 2023 were as follows (in thousands): Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Commercial revenue by product: RECELL $ 19,059 $ 13,547 $ 44,811 $ 35,673 Other wound care products 271 - 706 - Lease revenue 152 - 164 - Total commercial sales $ 19,482 $ 13,547 $ 45,681 $ 35,673 Cost of sales by customer type for the three-months and nine-months ended September 30, 2024 and 2023 were as follows (in thousands): Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Cost of sales: Commercial cost $ 3,190 $ 2,110 $ 6,814 $ 5,835 BARDA: Product cost - ( 83 ) - ( 106 ) Emergency preparedness service cost - 86 - 255 Total $ 3,190 $ 2,113 $ 6,814 $ 5,984

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears more likely than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. As of September 30, 2024 and December 31, 2023, the Company did no t have any outstanding or threatened litigation that would have a material impact on the Consolidated Financial Statements. Minimum Purchase Commitments with Stedical The Company is subject to minimum purchases of PermeaDerm product for the initial term of five years . For 2024, the Company has an obligation to purchase enough products from Stedical to achieve $ 5.0 million in customer sales of that purchased inventory . As of September 30, 2024, t his obligation has already been achieved. For the first three years of the Distribution Agreemen t, the minimum purchase should increase annually by an amount equal to the percentage growth in the Company's annual U.S.-based revenues excluding PermeaDerm revenue, or a minimum increase of at least 20 % over the prior year purchase commitment. After the third year, the minimum purchase obligation shall increase annually by an amount equal to the percentage growth of the Company's annual U.S.-based revenues excluding PermeaDerm sales. The minimum purchase obligation should never decrease from the previous year. Development and Distribution Agreement with Regenity On July 31, 2024, the Company entered into a multi-year exclusive development and distribution agreement with Collagen Matrix, Inc. dba Regenity Biosciences (“Regenity”) to market, sell, and distribute Cohealyx ™ , a unique collagen-based dermal matrix under the Company's private label in the U.S., with the potential to commercialize the product in countries in the European Union, as well as in Japan and Australia. The initial term of the agreement is five years , with an automatic extension of an additional five years , contingent upon meeting certain criteria. Under the terms of the agreement, the Company will make a $ 2.0 million payment upon receipt of 510(k) clearance by Regenity. The Company has a further obligation to make up to an additional $ 3.0 million payment on or before January 4, 2026 to guarantee development and manufacturing capacity (and related resources), contingent on positive results of certain clinical studies related to the new dermal matrix. These obligations are not recorded in the Company's Consolidated Balance Sheets.

Common and Preferred Stock

Common and Preferred Stock	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Common and Preferred Stock	12. Common and Preferred Stock The Company’s CHESS Depositary Interests (“CDIs”) are quoted on the ASX under the ticker code, “AVH.” The Company’s shares of Common stock are quoted on the Nasdaq Capital Market (“Nasdaq”) under the ticker code, “RCEL”. One share of Common Stock on Nasdaq is equivalent to five CDIs on the ASX. The Company is authorized to issue 200,000,000 shares of Common stock, par value $ 0.0001 per share, and 10,000,000 shares of preferred stock, par value $ 0.0001 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. Common stock held in the rabbi trust is classified in a manner similar to treasury stock and presented separately on the Consolidated Balance Sheets as Common stock held by the NQDC Plan. As of September 30, 2024, and December 31, 2023, 26,217,629 and 25,682,078 shares of Common stock, respectively, were issued and outstanding and no shares of Preferred stock were outstanding during any period.

Stock-Based Payment Plans

Stock-Based Payment Plans	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Payment Plans	13. Stock-Based Payment Plans Stock-Based Payment Expenses Stock-based payment transactions are recognized as compensation expense based on the fair value of the instrument on the date of grant. The Company uses the graded-vesting method to recognize compensation expense. Compensation cost is reduced for forfeitures as they occur in accordance with ASU 2016-09 , Simplifying the Accounting for Share-Based Payment. No income tax benefit was recognized in the Consolidated Statements of Operations for stock-based payment arrangements for the three-months and nine-months ended September 30, 2024 and 2023. In June 2023, the stockholders approved the ESPP, which became effective on July 1, 2023 . On June 30, 2023, the Company filed a Registration Statement on Form S-8 to register 1,000,000 shares of Common stock under the ESPP, as a result of the Company’s stockholders approving the ESPP at the 2023 Annual Meeting. The ESPP features two six-month offering periods per year, running from June 1 to November 30 and December 1 to May 31. The Company has included stock-based compensation expense for all equity awards and the ESPP as part of operating expenses in the accompanying Consolidated Statements of Operations as follows: Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Sales and marketing expenses $ 854 $ 513 $ 2,842 $ 915 General and administrative expenses 2,781 1,534 6,510 4,442 Research and development expenses 445 383 1,346 856 Total $ 4,080 $ 2,430 $ 10,698 $ 6,213 A summary of share option activity as of September 30, 2024, and changes during the period ended, is presented below: Service Only Share Options Performance-Based Share Options Total Share Options Outstanding shares at December 31, 2023 2,397,571 292,587 2,690,158 Granted 1,887,658 55,000 1,942,658 Exercised ( 247,795 ) ( 53,729 ) ( 301,524 ) Expired ( 252,436 ) ( 48,466 ) ( 300,902 ) Forfeited ( 231,185 ) ( 8,184 ) ( 239,369 ) Outstanding shares at September 30, 2024 3,553,813 237,208 3,791,021 Exercisable at September 30, 2024 1,146,550 163,322 1,309,872 Vested and expected to vest - September 30, 2024 3,553,813 237,208 3,791,021 A summary of the status of the Company’s unvested RSUs as of September 30, 2024, and changes that occurred during the period, is presented below: Unvested Shares Tenure-Based RSUs Performance Total RSUs Unvested RSUs outstanding at December 31, 2023 207,112 28,020 235,132 Granted 55,200 - 55,200 Vested ( 122,015 ) ( 15,759 ) ( 137,774 ) Forfeited ( 20,600 ) ( 3,504 ) ( 24,104 ) Unvested RSUs outstanding at September 30, 2024 119,697 8,757 128,454

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes Tax benefit (expense) for the three-months ended September 30, 2024 and 2023 was a benefit of $ 28,000 and expense of $ ( 11,000 ) , respectively. Tax expense for the nine-months ended September 30, 2024 and 2023 was $ ( 35,000 ) and $ ( 54,000 ) , respectively. These amounts are related to state minimum taxes.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	15. Net Loss per Share The following is a reconciliation of the basic and diluted loss per share computations: Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 (in thousands, except per share amounts) Net loss $ ( 16,205 ) $ ( 8,712 ) $ ( 50,256 ) $ ( 28,316 ) Weighted-average common shares—outstanding, basic and diluted 25,984 25,402 25,795 25,282 Net loss per common share, basic and diluted $ ( 0.62 ) $ ( 0.34 ) $ ( 1.95 ) $ ( 1.12 ) Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Anti-dilutive shares excluded from diluted net loss per common share: Stock options 3,791,021 2,684,683 3,791,021 2,684,683 Restricted stock units 128,454 292,272 128,454 292,272 ESPP 75,339 - 75,339 - Warrants 409,661 - 409,661 - The Company’s basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the relevant period. In accordance with ASC 710-10, Compensation - General , 122,294 shares of Common stock held by the rabbi trust are excluded from the denominator in the basic and diluted net loss per common share calculations. For the purposes of the calculation of diluted net loss per share, options to purchase common stock, restricted stock units and unvested shares of Common stock issued upon the early exercise of stock options have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive. Because the Company has reported a net loss for the three-months and nine-months ended September 30, 2024 and 2023, diluted net loss per common share is the same as the basic net loss per share for those periods.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that except as disclosed below, no events have occurred that would require adjustment to, or disclosures in, the Consolidated Financial Statements. On November 7, 2024, an affiliate of OrbiMed Advisors, LLC (the “Lender”) and the Company mutually agreed to a third amendment (the “Third Amendment”) to the Credit Agreement (See Note 6. Long-term debt). Under the terms of the Third Amendment and subject to the payment by the Company of a consent fee to the Lender, the Company and the Lender mutually agreed to (1) terminate two additional tranches of available debt in the aggregate amount of $ 50.0 million and (2) remove the trailing 12-month revenue covenant for the fourth quarter of 2024, which was set at $ 67.5 million. All revenue covenants for subsequent quarters remain in effect.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the Consolidated Financial Statements reflect all adjustments of a normal and recurring nature that are considered necessary for a fair presentation of the results for the interim periods presented. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year-ended December 31, 2023 filed with the SEC on February 22, 2024 and the Australian Securities Exchange (“ASX”) on February 23, 2024 (the “2023 Annual Report”). Except for revenue recognition, related to the RECELL GO system, as described below, there have been no changes to the Company’s significant accounting policies as described in the 2023 Annual Report that have had a material impact on the Company’s Consolidated Financial Statements. See the summary of the Company’s significant accounting policies set forth in the notes to its Consolidated Financial Statements included in the 2023 Annual Report.
Principles of Consolidation	Principles of Consolidation The accompanying Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07, S egment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (“CODM”) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU on its Consolidated Financial Statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments affected by this ASU require (i) enhanced disclosures in connection with an entity's effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. These amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of adopting this ASU on its Consolidated Financial Statements and disclosures.
Use of Estimates	Use of Estimates The preparation of the accompanying Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts (including the stand-alone selling price (“SSP” ) for the RPD, allowance for credit losses, reserves for inventory excess and obsolescence, carrying value of long-lived assets, the useful lives of long-lived assets, accounting for marketable securities, income taxes, fair value of debt, fair value of warrants and stock-based compensation) and related disclosures. Estimates have been prepared based on the current and available information. However, actual results could differ from estimated amounts.
Foreign Currency Translation and Foreign Currency Transactions	Foreign Currency Translation and Foreign Currency Transactions The financial position and results of operations of the Company’s operating non-U.S. subsidiaries are generally determined using the respective local currency as the functional currency of that subsidiary. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each period end. Income statement accounts are translated at the average rate of exchange prevailing during the period. Adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive loss in the Consolidated Balance Sheets. The Company’s non-operating subsidiaries that use the U.S. Dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period and nonmonetary assets and liabilities at historical rates. Gains and losses resulting from these remeasurements are included in earnings in the Consolidated Statement of Operations. Gains and losses for remeasurement were minimal during the three-months and nine-months ended September 30, 2024 and 2023. The Company records certain revenues and operating expenses in foreign currencies. These revenues and expenses are translated into U.S. Dollars based on the average exchange rate for the reporting period. Assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate in effect as of the balance sheet date. For the three and nine-months ended September 30, 2024, the Company incurred approximately $ 11,000 and $ 23,000 in losses included in Net loss in the Consolidated Statement of Operations, respectively. For the three and nine-months ended September 30, 2023, t he Company incurred approximately $ 26,000 and $ 23,000 in gains included in Net loss in the Consolidated Statement of Operations, respectively.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash held at deposit institutions and cash equivalents. Cash equivalents consist primarily of money market funds. Cash equivalents also include short-term highly liquid investments with original maturities of three months or less from the date of purchase. The Company holds cash at deposit institutions in the amount of $ 5.3 million and $ 10.7 million as of September 30, 2024 and December 31, 2023, respectively. The Company does no t have cash on deposit denominated in foreign currency in foreign institutions as of September 30, 2024. As of December 31, 2023, the Company had $ 69,000 of cash on deposit denominated in foreign currencies in foreign institutions. As of September 30, 2024 and December 31, 2023, the Company held cash equivalents in the amounts of $ 13.3 million and $ 11.4 million , respectively.
Rabbi Trust	Rabbi Trust During April 2022, the Company established a rabbi trust to hold the assets of the NQDC Plan. The rabbi trust holds the COLI asset and the Common stock from deferred restricted stock unit awards that have vested. The NQDC Plan permits diversification of fully vested shares into other equity securities subject to a six-month-and-one-day holding period. In accordance with ASR 268 , Redeemable Preferred Stock , and ASC 718 , Compensation — Stock Compensation , prior to vesting, the deferred share awards are classified as an equity instrument and changes in fair value of the amount owed to the participant are not recognized. The redemption amounts of the deferred awards are based on the vested percentage and are recorded outside of permanent equity as Non-qualified deferred compensation share awards on the Consolidated Balance Sheets. Common stock held in the rabbi trust is classified in a manner similar to treasury stock and presented separately on the Consolidated Balance Sheets as Company common stock held by the NQDC plan. As of September 30, 2024 and December 31, 2023, a total of 91,026 and 81,052 shares awards have been deferred, respectively. Vested shares are converted to Common stock and are reclassified to permanent equity.
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, and debt and other liabilities. As of September 30, 2024 and December 31, 2023, substantially all the Company’s cash and cash equivalents were deposited in accounts at financial institutions, and those deposited amounts exceed federally insured limits and are subject to the risk of bank failure. As of September 30, 2024 and December 31, 2023, no single commercial customer accounted for more than 10 % of net accounts receivable or more than 10 % of revenues for the three-months and nine-months ended September 30, 2024 and 2023.
Revenue Recognition	Revenue Recognition The Company generates revenues primarily from: • The sale of RECELL EOU, RPK, and PermeaDerm products to hospitals, other treatment centers, and distributors. • Maintenance fee received from BARDA to ensure first right of access to our inventory. In the prior year, the Company recorded service revenue for the emergency preparedness services provided to BARDA. • Lease revenue for the RPD. The Company’s sale of the RECELL EOU and PermeaDerm products are accounted for under ASC 606, Revenue from contracts with customers (“ASC 606”). Revenue for the RECELL GO system is disaggregated between two accounting standards: (1) ASC 606 for the RPK and (2) ASC 842, Leases (“ASC 842”) for the RPD. Revenues from BARDA are accounted for under ASC 606, and are included in Sales revenues within the Consolidated Statements of Operations. To determine revenue recognition for contracts that are within the scope of ASC 606, the Company performs the following five steps: 1. Identify the contract with a customer 2. Identify the performance obligations 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations 5. Recognize revenue when/as a performance obligation(s) is(are) satisfied In order for an arrangement to be considered a contract, it must be probable that the Company will collect the consideration to which it is entitled for goods or services to be transferred. The Company then assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. The Company determines the transaction price based on the amount of consideration the Company expects to receive for providing the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. When accounting for a contract that contains multiple performance obligations, the Company must develop judgmental assumptions to determine the estimated SSP for each performance obligation identified in the contract. We utilize the observable SSP when available, which represents the price charged for the promised product or service when sold separately. When the SSP for our products or services are not directly observable, we determine the SSP using relevant information available and apply suitable estimation methods including, but not limited to, the cost-plus margin approach. The Company then allocates the transaction price to each performance obligation based on the relative SSP and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. Most of the Company’s contracts have a single performance obligation. As such, the Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. Revenue is recognized net of volume discounts (variable consideration). For the Company’s contracts that have an original duration of one year or less, since contract inception and customer payment occur within the same period the Company does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract acquisition costs such as commissions and shipping and handling expenses as incurred. Revenue recognition for contracts that are within the scope of ASC 606 and ASC 842 The Company enters into contracts with customers where it receives consideration for the RPK and does not receive additional consideration for the RPD. As a result, judgment and analysis are required to determine the appropriate accounting, including: (i) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (ii) the amount of the total consideration, as well as variable consideration, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. For these contracts the Company considers the guidance under ASC 842 to determine if furnishing the RPD to the customer during the period of use establishes an embedded lease. To determine if the contract contains a lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company. As the contract conveys the right to control the use of an identified asset for a period of time, the contract was determined to contain a lease. The Company then evaluated the lease classification based on the below: • Pursuant to ASC 842-30, the Company will classify a lease as a sales-type lease if: (i) the lease transfers ownership of the underlying asset to the lessee by the end of the lease term, (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise, (iii) the lease term is for the major part of the remaining economic life of the underlying asset, (iv) the present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments equals or exceeds substantially all (90% or more) of the fair value of the underlying asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. • Pursuant to ASC 842-30, when none of the sales-type lease classification criteria are met, a lessor would classify the lease as a direct financing lease when both of the following criteria are met: (i) the present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments and/or any other third party unrelated to the lessor equals or exceeds substantially all (90% or more) of the fair value of the underlying asset and (ii) it is probable that the lessor will collect the lease payments plus any amount necessary to satisfy a residual value guarantee. • Pursuant to ASC 842-30, a lessor would classify a lease as an operating lease when none of the sales-type or direct financing lease classification criteria are met. Further, per ASC 842, a lessor is required to classify a lease with variable lease payments that do not depend on an index or rate as an operating lease at lease commencement if the lease would have been classified as a sales-type lease or a direct financing lease in accordance with the classification criteria of ASC 842 and the lessor would have otherwise recognized a loss at the lease commencement date. In determining whether the lease components are related to a sales-type lease or an operating lease, the Company evaluates if the lease transfers ownership at the end of the lease term, purchase options, the lease term in relation to the economic life of the asset, if the lease payments exceed the fair value of the asset, and if the asset is of a specialized nature. The Company also evaluates if the lease results in a loss at the lease commencement date. As the lease term is for the major part of the economic life, the lease meets the classification criteria for sales-type lease. However, t o determine if the contract results in a loss at the lease commencement date the Company evaluated the consideration in the contract. The consideration at lease commencement does not contain fixed payments, purchase options, penalty payments or residual value guarantees. The variable consideration is related to the sale of the RPK. As the variable lease payments are not dependent on an index or rate, the variable consideration is excluded from consideration at contract inception resulting in a loss at lease commencement. As such, the Company classifies the lease as an operating lease. The contracts contain a lease component, the RPD, and a non-lease component, the RPK. The lease component will be accounted for under the ASC 842 and the non-lease component will be accounted for under ASC 606, as described above. In accordance with ASC 842, the consideration in the contract will be allocated to each separate lease component and non-lease component of the contract. The consideration is allocated to these lease and non-lease components based on the SSP (as described above for contracts within the scope of ASC 606). In accordance with ASC 842, variable lease payments will be recognized once the sale of the RPK occurs and control has transferred to the customer. Consideration will be allocated to the RPD and RPK based on the SSP. Consideration related to the RPD will be recognized as Lease revenue and consideration related to the RPK will be recognized as Sales revenues in accordance with guidance in ASC 606, as described above, upon transfer of control of the RPK, which generally occurs at the time the product is shipped or delivered depending on the customer's shipping terms. Assets in our lease program are reported in Plant and equipment, net on our Consolidated Balance Sheets and are depreciated over the useful life of the RPD device's 200 uses, as indicated in the Instructions for Use that were approved by the FDA, and expensed as Costs of goods sold in the Consolidated Statements of Operations. The RPD depreciation has a direct relationship to the number of RPK units sold. Based on customer usage, each purchase of an RPK unit results in a 1/200 depreciation to the RPD .

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Securities, Available-for-Sale [Abstract]
Summary of Amortized Cost and Estimated Fair Values of Securities Available for Sale	The following table summarizes the amortized cost and estimated fair values of securities available-for-sale: As of September 30, 2024 Amortized Gross Gross Carrying (in thousands) Cash equivalents: Money market funds $ 13,357 $ - $ - $ 13,357 Total cash equivalents $ 13,357 $ - $ - $ 13,357 Current marketable securities: U.S. Treasury securities $ 25,732 $ 34 $ - $ 25,766 Total current marketable securities $ 25,732 $ 34 $ - $ 25,766 As of December 31, 2023 Amortized Gross Gross Carrying (in thousands) Cash equivalents: Money market funds $ 8,427 $ - $ - $ 8,427 U.S. Treasury securities 2,992 - - 2,992 Total cash equivalents $ 11,419 $ - $ - $ 11,419 Current marketable securities: U.S. Treasury securities $ 65,145 $ 100 $ ( 3 ) $ 65,242 U.S. Government agency obligations 1,699 - ( 2 ) 1,697 Total current marketable securities $ 66,844 $ 100 $ ( 5 ) $ 66,939
Summary of Maturities of Available-for-Sale Securities	The maturities of our available-for-sale securities are summarized in the following table using contractual maturities. Actual maturities may differ from contractual maturities due to obligations that are called or prepaid. As of September 30, 2024 As of December 31, 2023 (in thousands) Amortized Carrying Amortized Carrying Due in one year or less $ 25,732 $ 25,766 $ 66,844 $ 66,939

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Summary of Financial Assets Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy: As of September 30, 2024 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 13,357 $ - $ - $ 13,357 Total cash equivalents $ 13,357 $ - $ - $ 13,357 Current marketable securities: U.S. Treasury securities $ - $ 25,766 $ - $ 25,766 Total current marketable securities $ - $ 25,766 $ - $ 25,766 Total marketable securities and cash equivalents $ 13,357 $ 25,766 $ - $ 39,123 Financial liabilities: Long-term debt $ - $ - $ 42,547 $ 42,547 Warrant liability - - 2,759 $ 2,759 Non-qualified deferred compensation plan liability - 4,612 - $ 4,612 Total financial liabilities $ - $ 4,612 $ 45,306 $ 49,918 Financial assets: Corporate-owned life insurance policies $ - $ 3,059 $ - $ 3,059 Total financial assets $ - $ 3,059 $ - $ 3,059 As of December 31, 2023 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 8,427 $ - $ - $ 8,427 U.S. Treasury securities - 2,992 - 2,992 Total cash equivalents $ 8,427 $ 2,992 $ - $ 11,419 Current marketable securities: U.S. Treasury securities $ - $ 65,242 $ - $ 65,242 U.S. Government agency obligations - 1,697 - 1,697 Total current marketable securities $ - $ 66,939 $ - $ 66,939 Total marketable securities and cash equivalents $ 8,427 $ 69,931 $ - $ 78,358 Financial liabilities: Long-term debt $ - $ - $ 39,812 $ 39,812 Warrant liability - - 3,158 3,158 Non-qualified deferred compensation plan liability - 3,831 - $ 3,831 Total financial liabilities $ - $ 3,831 $ 42,970 $ 46,801 Financial assets: Corporate-owned life insurance policies $ - $ 2,475 $ - $ 2,475 Total financial assets $ - $ 2,475 $ - $ 2,475
Summary of Fair Value Measurement Inputs and Valuation Techniques	The below assumptions were used in the MCS: September 30, 2024 December 31, 2023 Risk-free interest rate 3.53 % 3.81 % Revenue volatility 64.00 % 64.00 % Revenue discount rate 14.41 % 16.58 % The fair value of the warrant liability, which is reported within Warrant liability on the Consolidated Balance Sheets, is estimated by the Company based on the Black-Scholes option pricing model with the follow ing key inputs: September 30, 2024 December 31, 2023 Price of common stock $ 10.72 $ 13.72 Expected term 9.05 years 9.81 years Expected volatility 51.47 % 31.07 % Exercise price $ 10.9847 $ 10.9847 Risk-free interest rate 3.73 % 3.84 % Expected dividends 0.00 % 0.00 %
Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Summary of Changes in Fair Value	The following table presents the summary of changes in the fair value of our Level 3 financial instruments: As of September 30, 2024 As of December 31, 2023 (in thousands) Long-term debt Warrant liability Long-term debt Warrant liability Balance beginning of period $ 39,812 $ 3,158 $ - $ - Fair value on issuance date 37,575 2,425 Change in fair value in earnings 2,619 ( 399 ) 1,616 733 Change in fair value in other comprehensive loss 116 - 621 - Balance end of period, at fair value $ 42,547 $ 2,759 $ 39,812 $ 3,158

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Summary Of Composition Of Inventory	The composition of the inventory is as follows (in thousands): As of September 30, 2024 December 31, 2023 Raw materials $ 2,731 $ 3,683 Work in process 427 878 Finished goods 3,071 1,035 Total inventory $ 6,229 $ 5,596

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Summary Of Composition Of Intangible Assets	The composition of intangible assets, net is as follows (in thousands): As of September 30, 2024 As of December 31, 2023 Weighted Gross Accumulated Net Gross Accumulated Net Patent 1 - $ - $ - $ - $ 17 $ ( 17 ) $ - Patent 2 12 136 ( 43 ) 93 141 ( 39 ) 102 Patent 3 14 234 ( 65 ) 169 206 ( 54 ) 152 Patent 5 18 108 ( 15 ) 93 99 ( 11 ) 88 Patent 6 16 62 ( 9 ) 53 56 ( 6 ) 50 Patent 7 - - - - 2 - 2 Patent 8 18 42 ( 3 ) 39 29 ( 1 ) 28 Patent 9 2 117 ( 28 ) 89 3 - 3 Patent 10 - - - - 3 - 3 Patent 11 - - - - 6 ( 1 ) 5 Trademarks Indefinite 54 - 54 54 - 54 Total intangible assets $ 753 $ ( 163 ) $ 590 $ 616 $ ( 129 ) $ 487
Summary Of Future Amortization Of Amortizable Intangible Assets Held	The Company expects the future amortization of amortizable intangible assets held at September 30, 2024 to be as follows (in thousands): Estimated Amortization Expense Remainder of 2024 $ 47 2025 93 2026 49 2027 40 2028 40 Thereafter 267 Total $ 536

Plant and Equipment (Tables)

Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Summary of Composition of Plant and Equipment	The composition of plant and equipment, net is as follows (in thousands): As of Useful Lives September 30, 2024 December 31, 2023 Computer equipment 3 - 5 years $ 1,632 $ 984 Computer software 3 years 836 840 Construction in progress (“CIP”) 90 87 Furniture and fixtures 7 years 1,112 824 Laboratory and other equipment 3 - 5 years 954 769 Leasehold improvements Lesser of life or lease term 4,196 367 RECELL moulds 5 years 462 438 RECELL GO RPD CIP 1,531 - RECELL GO RPD 318 - Operating lease assets - RPD 200 uses 1,071 - Less: accumulated amortization and depreciation ( 3,051 ) ( 2,432 ) Total plant and equipment, net $ 9,151 $ 1,877
Summary Of Lease Revenues	The table below summarizes the Company's Lease revenue as presented in the Consolidated Statement of Operations for the three and nine-months ended September 30, 2024 and 2023. Three-Months Ended Nine-Months Ended (in thousands) September 30, 2024 September 30, 2024 Variable lease revenue $ 152 164
Summary Of Assets Held For Lease And Included In Plant And Equipment	Assets held for lease and included in Plant and equipment consisted of the following (in thousands): As of September 30, 2024 Rental RPD assets $ 1,071 Accumulated depreciation ( 24 ) Net rental RPD assets $ 1,047

Reporting Segment and Geograp_2

Reporting Segment and Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule Of Revenue By Region And Customer Type, Commercial Revenue By Product And Cost of Sales By Customer Type	Revenue by region for the three-months and nine-months ended September 30, 2024 and 2023 were as follows (in thousands): Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Revenue by region: United States $ 19,048 $ 12,961 $ 44,162 $ 33,379 Japan 388 581 1,237 2,309 European Union - - 155 - Australia 54 61 132 156 United Kingdom 56 42 159 104 Total $ 19,546 $ 13,645 $ 45,845 $ 35,948 Revenue by customer type for the three-months and nine-months ended September 30, 2024 and 2023 were as follows (in thousands): Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Revenue by customer type: Commercial sales $ 19,482 $ 13,547 $ 45,681 $ 35,673 Deferred commercial revenue recognized 8 8 25 25 BARDA revenue for right of first access 56 90 139 250 Total $ 19,546 $ 13,645 $ 45,845 $ 35,948 Commercial revenue by product for the three-months and nine-months ended September 30, 2024 and 2023 were as follows (in thousands): Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Commercial revenue by product: RECELL $ 19,059 $ 13,547 $ 44,811 $ 35,673 Other wound care products 271 - 706 - Lease revenue 152 - 164 - Total commercial sales $ 19,482 $ 13,547 $ 45,681 $ 35,673 Cost of sales by customer type for the three-months and nine-months ended September 30, 2024 and 2023 were as follows (in thousands): Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Cost of sales: Commercial cost $ 3,190 $ 2,110 $ 6,814 $ 5,835 BARDA: Product cost - ( 83 ) - ( 106 ) Emergency preparedness service cost - 86 - 255 Total $ 3,190 $ 2,113 $ 6,814 $ 5,984

Stock-Based Payment Plans (Tabl

Stock-Based Payment Plans (Tables)	9 Months Ended
	Sep. 30, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Stock-based Compensation For All Equity Awards And The ESPP Reflected In The Statements Of Operations	The Company has included stock-based compensation expense for all equity awards and the ESPP as part of operating expenses in the accompanying Consolidated Statements of Operations as follows: Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Sales and marketing expenses $ 854 $ 513 $ 2,842 $ 915 General and administrative expenses 2,781 1,534 6,510 4,442 Research and development expenses 445 383 1,346 856 Total $ 4,080 $ 2,430 $ 10,698 $ 6,213
Summary Of Share Option Activity	A summary of share option activity as of September 30, 2024, and changes during the period ended, is presented below: Service Only Share Options Performance-Based Share Options Total Share Options Outstanding shares at December 31, 2023 2,397,571 292,587 2,690,158 Granted 1,887,658 55,000 1,942,658 Exercised ( 247,795 ) ( 53,729 ) ( 301,524 ) Expired ( 252,436 ) ( 48,466 ) ( 300,902 ) Forfeited ( 231,185 ) ( 8,184 ) ( 239,369 ) Outstanding shares at September 30, 2024 3,553,813 237,208 3,791,021 Exercisable at September 30, 2024 1,146,550 163,322 1,309,872 Vested and expected to vest - September 30, 2024 3,553,813 237,208 3,791,021
Non Option Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Share Option Activity	A summary of the status of the Company’s unvested RSUs as of September 30, 2024, and changes that occurred during the period, is presented below: Unvested Shares Tenure-Based RSUs Performance Total RSUs Unvested RSUs outstanding at December 31, 2023 207,112 28,020 235,132 Granted 55,200 - 55,200 Vested ( 122,015 ) ( 15,759 ) ( 137,774 ) Forfeited ( 20,600 ) ( 3,504 ) ( 24,104 ) Unvested RSUs outstanding at September 30, 2024 119,697 8,757 128,454

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Summary Of Reconciliation Of The Basic And Diluted Loss Per Share	The following is a reconciliation of the basic and diluted loss per share computations: Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 (in thousands, except per share amounts) Net loss $ ( 16,205 ) $ ( 8,712 ) $ ( 50,256 ) $ ( 28,316 ) Weighted-average common shares—outstanding, basic and diluted 25,984 25,402 25,795 25,282 Net loss per common share, basic and diluted $ ( 0.62 ) $ ( 0.34 ) $ ( 1.95 ) $ ( 1.12 ) Three-Months Ended Nine-Months Ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Anti-dilutive shares excluded from diluted net loss per common share: Stock options 3,791,021 2,684,683 3,791,021 2,684,683 Restricted stock units 128,454 292,272 128,454 292,272 ESPP 75,339 - 75,339 - Warrants 409,661 - 409,661 -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Use shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) shares
Summary Of Significant Accounting Policies [Line Items]
Gain (loss) on foreign currency transactions	$ (11,000)	$ 26,000	$ (23,000)	$ 23,000
Cash at deposit institutions	5,300,000		5,300,000		$ 10,700,000
Cash in foreign institutions	0		0		69,000
Cash equivalents held	$ 13,300,000		$ 13,300,000		$ 11,400,000
Number of shares awards deferred, unvested | shares			91,026		81,052
Commercial Customer | Revenue Benchmark | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	10%	10%	10%	10%
Commercial Customer | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, customer			no		no
Commercial Customer | Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage			10%		10%
RPD Devices
Summary Of Significant Accounting Policies [Line Items]
Plant and equipment, useful life | Use			200
Plant and equipment, description of depreciation			each purchase of an RPK unit results in a 1/200 depreciation to the RPD

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Estimated Fair Values of Securities Available for Sale (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	$ 25,732	$ 66,844
Gross Unrealized Holding Gains, Current marketable securities	34	100
Gross Unrealized Holding Losses, Current marketable securities		(5)
Carrying Value, Current marketable securities	25,766	66,939
Cash Equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	13,357	11,419
Carrying Value	13,357	11,419
U.S Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	25,732	65,145
Gross Unrealized Holding Gains, Current marketable securities	34	100
Gross Unrealized Holding Losses, Current marketable securities		(3)
Carrying Value, Current marketable securities	25,766	65,242
U.S Treasury Securities | Cash Equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		2,992
Carrying Value		2,992
Money Market Funds | Cash Equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	13,357	8,427
Carrying Value	$ 13,357	8,427
U.S Government Agency Obligations
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities		1,699
Gross Unrealized Holding Losses, Current marketable securities		(2)
Carrying Value, Current marketable securities		$ 1,697

Marketable Securities - Summa_2

Marketable Securities - Summary of Maturities of Available-for-Sale Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule Of Available For Sale Securities [Line Items]
Investment, Type [Extensible Enumeration]	Contractual Maturities [Member]	Contractual Maturities [Member]
Available for sale securities, Due in one year or less, Amortized cost	$ 25,732	$ 66,844
Available for sale securities, Due in one year or less, Carrying value	$ 25,766	$ 66,939

Marketable Securities - Additio

Marketable Securities - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Schedule Of Available For Sale Securities [Line Items]
Net unrealized gain (loss) on marketable securities			$ 34,000		$ 95,000
Credit loss recognized	$ 0		0		0
Sales of investments	0	$ 0	0	$ 0
Prepaids and Other Current Assets
Schedule Of Available For Sale Securities [Line Items]
Accrued interest income receivable	$ 154,000		$ 154,000		$ 227,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total current marketable securities	$ 25,766	$ 66,939
Fair Value on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	13,357	11,419
Total current marketable securities	25,766	66,939
Total marketable securities and cash equivalents	39,123	78,358
Total financial liabilities	49,918	46,801
Total financial assets	3,059	2,475
Fair Value on Recurring Basis | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	13,357	8,427
Total marketable securities and cash equivalents	13,357	8,427
Fair Value on Recurring Basis | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents		2,992
Total current marketable securities	25,766	66,939
Total marketable securities and cash equivalents	25,766	69,931
Total financial liabilities	4,612	3,831
Total financial assets	3,059	2,475
Fair Value on Recurring Basis | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	45,306	42,970
Long-term Debt | Fair Value on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	42,547	39,812
Long-term Debt | Fair Value on Recurring Basis | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	42,547	39,812
Warrant Liability | Fair Value on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	2,759	3,158
Warrant Liability | Fair Value on Recurring Basis | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	2,759	3,158
Non-qualified Deferred Compensation Plan Liability | Fair Value on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	4,612	3,831
Non-qualified Deferred Compensation Plan Liability | Fair Value on Recurring Basis | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	4,612	3,831
Money Market Funds | Fair Value on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	13,357	8,427
Money Market Funds | Fair Value on Recurring Basis | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	13,357	8,427
U.S Treasury Securities | Fair Value on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents		2,992
Total current marketable securities	25,766	65,242
U.S Treasury Securities | Fair Value on Recurring Basis | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents		2,992
Total current marketable securities	25,766	65,242
U.S. Government Agency Obligations | Fair Value on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total current marketable securities		1,697
U.S. Government Agency Obligations | Fair Value on Recurring Basis | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total current marketable securities		1,697
Corporate-owned Life Insurance Policies | Fair Value on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	3,059	2,475
Corporate-owned Life Insurance Policies | Fair Value on Recurring Basis | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 3,059	$ 2,475

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary Of Changes In The Fair Value Of Our Level 3 Financial Instruments (Details) - Level 3 - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Long-term Debt
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance beginning of period	$ 39,812
Fair value on issuance date		$ 37,575
Change in fair value in earnings	2,619	1,616
Change in fair value in other comprehensive loss	116	621
Balance end of period, at fair value	42,547	39,812
Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance beginning of period	3,158
Fair value on issuance date		2,425
Change in fair value in earnings	(399)	733
Balance end of period, at fair value	$ 2,759	$ 3,158

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	Sep. 30, 2024 Iteration
Monte Carlo Simulation | Measurement Input, Revenue Multiple
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of iterations of various simulated revenues to determine fair value of debt	100,000

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Fair Value Measurement Inputs and Valuation Techniques (Details) - Level 3	Sep. 30, 2024 USD ($) yr	Dec. 31, 2023 yr USD ($)
Risk-free interest rate | Monte Carlo Simulation
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	0.0353	0.0381
Risk-free interest rate | Black Scholes Option Pricing Model
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	0.0373	0.0384
Revenue volatility | Monte Carlo Simulation
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	0.64	0.64
Revenue discount rate | Monte Carlo Simulation
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	0.1441	0.1658
Price of common stock | Black Scholes Option Pricing Model
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	10.72	13.72
Expected term | Black Scholes Option Pricing Model
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input | yr	9.05	9.81
Expected volatility | Black Scholes Option Pricing Model
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	51.47	31.07
Exercise price | Black Scholes Option Pricing Model
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	10.9847	10.9847
Expected dividends | Black Scholes Option Pricing Model
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	0	0

Revenues - Additional Informati

Revenues - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Sales revenue	$ 19,394,000	$ 13,645,000	$ 45,681,000	$ 35,948,000
Lease revenue	152,000		164,000
Performance obligation estimated revenue expected to be recognised	365,000		365,000		$ 390,000
Contract with customer assets	0		0		0
Contract with customers non current liability	332,000		332,000		357,000
Other Current Liabilities
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract with customers current liability	33,000		33,000		33,000
Contract Liabilities
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract with customers non current liability	332,000		332,000		357,000
RPK
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Sales revenue	7,600,000		$ 8,200,000
PermeaDerm
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Gross margin from sale of average sale price			50%
Percentage of gross revenue from the sale of products			50%
COSMOTEC
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract with customer liabilities	365,000		$ 365,000		$ 390,000
Contract with customer liability revenue recognized	$ 8,000	$ 8,000	$ 25,000	$ 25,000

Long-term Debt - Additional Inf

Long-term Debt - Additional Information (Details) - USD ($)		3 Months Ended		9 Months Ended
	Oct. 18, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Line of Credit Facility [Line Items]
Common stock par value		$ 0.0001		$ 0.0001		$ 0.0001
Net product sale equals or exceeds amount		$ 19,546,000	$ 13,645,000	$ 45,845,000	$ 35,948,000
Debt instrument unpaid principal balance		40,000,000		40,000,000
Debt instrument outstanding amount addition (reduction) to liability		$ 2,500,000		$ 2,500,000		$ (188,000)
Senior Secured Credit Facility | OrbiMed
Line of Credit Facility [Line Items]
Common stock par value	$ 0.0001
Credit agreement term	5 years
Line of credit facility description				On October 18, 2023 (the “Closing Date”) the Company entered into a credit agreement, by and between the Company, as borrower, and an affiliate of OrbiMed Advisors, LLC (the “Lender”) as the lender and administrative agent (the “Credit Agreement”). The Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $90.0 million, of which (i) $40.0 million was made available on the Closing Date (the “Initial Commitment Amount”), (ii) $25.0 million is available, at the Company’s discretion, on or prior to December 31, 2024, subject to certain net revenue requirements, and (iii) $25.0 million is available, at the Company’s discretion, on or prior to June 30, 2025, subject to certain net revenue requirements (the “Loan Facility”). The maturity date of the Credit Agreement is October 18, 2028 (the “Maturity Date”). On the Closing Date, the Company closed on the Initial Commitment Amount, less certain fees and expenses payable to or on behalf of the Lender. The Company received net proceeds of $38.8 million upon closing after deducting the Lender's transaction costs in connection with the Loan Facility.
Aggregate principal amount	$ 90,000,000
Current borrowing capacity	$ 40,000,000
Maturity date	Oct. 18, 2028
Proceeds from debt, net of issuance costs	$ 38,800,000
Line of credit facility, exit fee percentage	3%
Quarterly installment percentage of outstanding principal amount	5%
Repayments on outstanding debt				$ 0
Debt Instrument, fixed percentage	4%	13.20%		13.20%
Debt Instrument, variable percentage	8%
Unused fee accrues percentage of undrawn balance amount	0.50%
Warrants, exercise price	$ 10.9847
Warrants, expiration term	10 years
Senior Secured Credit Facility | OrbiMed | Maximum
Line of Credit Facility [Line Items]
Line of credit facility, repayment premium percentage	3%
Number of shares purchased, warrants	409,661
Senior Secured Credit Facility | OrbiMed | Minimum
Line of Credit Facility [Line Items]
Line of credit facility, repayment premium percentage	0%
Unrestricted cash and cash equivalents	$ 10,000,000
Senior Secured Credit Facility | OrbiMed | First Tranche On or Prior to December 31, 2024
Line of Credit Facility [Line Items]
Remaining borrowing capacity	25,000,000
Senior Secured Credit Facility | OrbiMed | Second Tranche On or Prior to June 30, 2025
Line of Credit Facility [Line Items]
Remaining borrowing capacity	$ 25,000,000

Leases - Summary Of Supplementa

Leases - Summary Of Supplemental Balance Sheet Information Related To Operating Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Disclosure Of Supplemental Balance Sheet Information Related To Operating Leases [Abstract]
Operating lease right-of-use assets	$ 3,780	$ 2,440
Operating lease liabilities, long-term	$ 3,079	$ 1,702

Inventory - Summary Of Composit

Inventory - Summary Of Composition Of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 2,731	$ 3,683
Work in process	427	878
Finished goods	3,071	1,035
Total inventory	$ 6,229	$ 5,596

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Inventory Disclosure [Abstract]
Excess and obsolete inventory related charges	$ 173,000	$ 81,000	$ 408,000	$ 149,000

Intangible Assets - Summary Of

Intangible Assets - Summary Of Composition Of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 753	$ 616
Finite Lived Intangible Assets, Accumulated Amortization	(163)	(129)
Finite Lived Intangible Assets, Net Carrying Amount	536
Intangible Assets, Net (Excluding Goodwill)	590	487
Trademarks
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 54	54
Patent 1
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Finite Lived Intangible Assets, Gross Amount		17
Finite Lived Intangible Assets, Accumulated Amortization		(17)
Patent 2
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
Finite Lived Intangible Assets, Gross Amount	$ 136	141
Finite Lived Intangible Assets, Accumulated Amortization	(43)	(39)
Finite Lived Intangible Assets, Net Carrying Amount	$ 93	102
Patent 3
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	14 years
Finite Lived Intangible Assets, Gross Amount	$ 234	206
Finite Lived Intangible Assets, Accumulated Amortization	(65)	(54)
Finite Lived Intangible Assets, Net Carrying Amount	$ 169	152
Patent 5
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	18 years
Finite Lived Intangible Assets, Gross Amount	$ 108	99
Finite Lived Intangible Assets, Accumulated Amortization	(15)	(11)
Finite Lived Intangible Assets, Net Carrying Amount	$ 93	88
Patent 6
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	16 years
Finite Lived Intangible Assets, Gross Amount	$ 62	56
Finite Lived Intangible Assets, Accumulated Amortization	(9)	(6)
Finite Lived Intangible Assets, Net Carrying Amount	$ 53	50
Patent 7
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Finite Lived Intangible Assets, Gross Amount		2
Finite Lived Intangible Assets, Net Carrying Amount		2
Patent 8
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	18 years
Finite Lived Intangible Assets, Gross Amount	$ 42	29
Finite Lived Intangible Assets, Accumulated Amortization	(3)	(1)
Finite Lived Intangible Assets, Net Carrying Amount	$ 39	28
Patent 9
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	2 years
Finite Lived Intangible Assets, Gross Amount	$ 117	3
Finite Lived Intangible Assets, Accumulated Amortization	(28)
Finite Lived Intangible Assets, Net Carrying Amount	$ 89	3
Patent 10
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Finite Lived Intangible Assets, Gross Amount		3
Finite Lived Intangible Assets, Net Carrying Amount		3
Patent 11
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Finite Lived Intangible Assets, Gross Amount		6
Finite Lived Intangible Assets, Accumulated Amortization		(1)
Finite Lived Intangible Assets, Net Carrying Amount		$ 5

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 0	$ 0
Amortization of intangible assets	$ 23,000	$ 9,000	$ 56,000	$ 26,000
Patents
Finite-Lived Intangible Assets [Line Items]
Loss on disposal for intangible assets			$ 16,000	$ 4,000

Intangible Assets - Summary o_2

Intangible Assets - Summary of Future Amortization of Amortizable Intangible assets held (Detail) $ in Thousands	Sep. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2024	$ 47
2025	93
2026	49
2027	40
2028	40
Thereafter	267
Finite Lived Intangible Assets, Net Carrying Amount	$ 536

Plant and Equipment - Summary o

Plant and Equipment - Summary of Composition of Plant and Equipment (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) Use	Dec. 31, 2023 USD ($)
Property, Plant and Equipment [Line Items]
Less: accumulated amortization and depreciation	$ (3,051)	$ (2,432)
Total plant and equipment, net	9,151	1,877
Computer Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 1,632	984
Computer Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer Software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	$ 836	840
Construction In Progress ("CIP")
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 90	87
Furniture And Fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Property, Plant and Equipment, Gross	$ 1,112	824
Laboratory and Other Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 954	769
Laboratory and Other Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Laboratory and Other Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember
Property, Plant and Equipment, Gross	$ 4,196	367
RECELL Moulds
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Gross	$ 462	$ 438
RECELL GO RPD CIP
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,531
RECELL GO RPD
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 318
Operating Lease Assets - RPD
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life | Use	200
Property, Plant and Equipment, Gross	$ 1,071

Plant and Equipment - Additiona

Plant and Equipment - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Use	Sep. 30, 2023 USD ($)
Property, Plant and Equipment [Line Items]
Depreciation	$ 288,000	$ 156,000	$ 661,000	$ 419,000
Impairment of fixed assets	$ 0
Loss on fixed asset disposal			$ 25,000	83,000
RPDs useful life | Use			200
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]	General and Administrative Expense
General and Administrative Expense
Property, Plant and Equipment [Line Items]
Loss on fixed asset disposal		$ 80,000	$ 5,000	$ 83,000

Plant and Equipment - Summary_2

Plant and Equipment - Summary Of Lease Revenues (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Operating Lease, Lease Income [Abstract]
Variable lease revenue	$ 152	$ 164

Plant and Equipment - Summary_3

Plant and Equipment - Summary Of Assets Held For Lease And Included In Plant And Equipment (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Property, Plant, and Equipment, Lessor Asset under Operating Lease [Abstract]
Rental RPD assets	$ 1,071
Accumulated depreciation	(24)
Net rental RPD assets	$ 1,047

Other Current and Long-Term Ass

Other Current and Long-Term Assets and Liabilities - Summary of Prepaids and Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Total prepaids and other current assets	$ 2,892	$ 1,659

Other Current and Long-Term A_2

Other Current and Long-Term Assets and Liabilities - Summary of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Other Liabilities, Current [Abstract]
Total other current liabilities	$ 1,308	$ 1,266

Reporting Segment and Geograp_3

Reporting Segment and Geographic Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2024 Segment
Segment Reporting [Abstract]
Number of reporting segment	1

Reporting Segment and Geograp_4

Reporting Segment and Geographic Information - Schedule Of Revenue By Region And Customer Type, Commercial Revenue By Product And Cost of Sales By Customer Type (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Revenues	$ 19,546	$ 13,645	$ 45,845	$ 35,948
Cost of sales
Cost of sales	3,190	2,113	6,814	5,984
BARDA deferred costs				(147)
Commercial Sales
Revenue:
Revenues	19,482	13,547	45,681	35,673
Cost of sales
Cost of sales	3,190	2,110	6,814	5,835
Commercial Sales | RECELL
Revenue:
Revenues	19,059	13,547	44,811	35,673
Commercial Sales | Other Wound Care Products
Revenue:
Revenues	271		706
Commercial Sales | Lease Revenue
Revenue:
Revenues	152		164
Deferred Commercial Revenue Recognized
Revenue:
Revenues	8	8	25	25
BARDA Revenue For Right of First Access
Revenue:
Revenues	56	90	139	250
Product Cost
Cost of sales
BARDA deferred costs		(83)		(106)
Emergency Preparedness Service Cost
Cost of sales
BARDA deferred costs		86		255
United States
Revenue:
Revenues	19,048	12,961	44,162	33,379
Japan
Revenue:
Revenues	388	581	1,237	2,309
European Union
Revenue:
Revenues	0		155
Australia
Revenue:
Revenues	54	61	132	156
United Kingdom
Revenue:
Revenues	$ 56	$ 42	$ 159	$ 104

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)		9 Months Ended
	Jul. 31, 2024	Sep. 30, 2024	Dec. 31, 2024	Dec. 31, 2023
Regenity Biosciences
Term of agreement	5 years
Extension term of agreement	5 years
Payment upon receipt of 510(k) clearance	$ 2,000,000
Additional payment term	on or before January 4, 2026
Regenity Biosciences | Maximum
Additional payment to guarantee manufacturing capacity	$ 3,000,000
Threatened Litigation
Litigation liability		$ 0		$ 0
Stedical Scientific, Inc. | PermeaDerm
Term of agreement		5 years
Purchase agreement, description		For the first three years of the Distribution Agreement, the minimum purchase should increase annually by an amount equal to the percentage growth in the Company's annual U.S.-based revenues excluding PermeaDerm revenue, or a minimum increase of at least 20% over the prior year purchase commitment. After the third year, the minimum purchase obligation shall increase annually by an amount equal to the percentage growth of the Company's annual U.S.-based revenues excluding PermeaDerm sales. The minimum purchase obligation should never decrease from the previous year.
Minimum percentage increase over prior year purchase commitment		20%
Scenario Forecast | Stedical Scientific, Inc. | PermeaDerm
Purchase obligation			$ 5,000,000

Common and Preferred Stock - Ad

Common and Preferred Stock - Additional Information (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Class Of Stock [Line Items]
Common stock shares authorized	200,000,000	200,000,000
Common stock par value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock par value	$ 0.0001	$ 0.0001
Common stock shares issued	26,217,629	25,682,078
Common stock shares outstanding	26,217,629	25,682,078
Preferred stock shares outstanding	0	0
Shareholders Of Avita Medical | ADRS
Class Of Stock [Line Items]
Reverse stock split ratio, description	One share of Common Stock on Nasdaq is equivalent to five CDIs on the ASX.

Stock-Based Payment Plans - Add

Stock-Based Payment Plans - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefit (expense)		$ 0	$ 0	$ 0	$ 0
ESPP purchase, Shares	1,000,000
Employee stock purchase plan effective date	Jul. 01, 2023

Stock-Based Payment Plans - Sum

Stock-Based Payment Plans - Summary Of Stock-based Compensation For All Equity Awards And The ESPP Reflected In The Statements Of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total	$ 4,080	$ 2,430	$ 10,698	$ 6,213
Selling and Marketing Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total	854	513	2,842	915
General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total	2,781	1,534	6,510	4,442
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total	$ 445	$ 383	$ 1,346	$ 856

Stock-Based Payment Plans - S_2

Stock-Based Payment Plans - Summary Of Share Option Activity (Detail) - shares	9 Months Ended
	Sep. 30, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	2,690,158
Granted	1,942,658
Exercised	(301,524)
Expired	(300,902)
Forfeited	(239,369)
Ending balance	3,791,021
Exercisable	1,309,872
Vested and expected to vest	3,791,021
Service Only Share Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	2,397,571
Granted	1,887,658
Exercised	(247,795)
Expired	(252,436)
Forfeited	(231,185)
Ending balance	3,553,813
Exercisable	1,146,550
Vested and expected to vest	3,553,813
Performance Based Share Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	292,587
Granted	55,000
Exercised	(53,729)
Expired	(48,466)
Forfeited	(8,184)
Ending balance	237,208
Exercisable	163,322
Vested and expected to vest	237,208

Stock-Based Payment Plans - S_3

Stock-Based Payment Plans - Summary Of Company Unvested RSUs (Detail)	9 Months Ended
	Sep. 30, 2024 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested RSUs beginning balance	235,132
Unvested RSUs granted	55,200
Unvested RSUs vested	(137,774)
Unvested RSUs forfeited	(24,104)
Unvested RSUs ending balance	128,454
Non Options Tenure Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested RSUs beginning balance	207,112
Unvested RSUs granted	55,200
Unvested RSUs vested	(122,015)
Unvested RSUs forfeited	(20,600)
Unvested RSUs ending balance	119,697
Non Option Performance Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested RSUs beginning balance	28,020
Unvested RSUs vested	(15,759)
Unvested RSUs forfeited	(3,504)
Unvested RSUs ending balance	8,757

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Line Items]
Income tax benefit (expense)	$ (28,000)	$ 11,000	$ 35,000	$ 54,000

Net Loss per Share - Summary of

Net Loss per Share - Summary of Reconciliation of The Basic And Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net loss	$ (16,205)	$ (8,712)	$ (50,256)	$ (28,316)
Weighted-average common shares – outstanding, basic	25,983,929	25,401,754	25,794,690	25,281,920
Weighted-average common shares – outstanding, diluted	25,983,929	25,401,754	25,794,690	25,281,920
Net loss per common share, basic	$ (0.62)	$ (0.34)	$ (1.95)	$ (1.12)
Net loss per common share, diluted	$ (0.62)	$ (0.34)	$ (1.95)	$ (1.12)

Net Loss per Share - Summary _2

Net Loss per Share - Summary of Anti-dilutive shares Excluded From Diluted Net Loss Per Common share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share, Diluted, Other Disclosure [Abstract]
Aggregate number of common equivalent shares excluded from computations of diluted net loss per common share (in shares)			122,294
Stock options
Earnings Per Share, Diluted, Other Disclosure [Abstract]
Aggregate number of common equivalent shares excluded from computations of diluted net loss per common share (in shares)	3,791,021	2,684,683	3,791,021	2,684,683
Restricted stock units
Earnings Per Share, Diluted, Other Disclosure [Abstract]
Aggregate number of common equivalent shares excluded from computations of diluted net loss per common share (in shares)	128,454	292,272	128,454	292,272
ESPP
Earnings Per Share, Diluted, Other Disclosure [Abstract]
Aggregate number of common equivalent shares excluded from computations of diluted net loss per common share (in shares)	75,339		75,339
Warrants
Earnings Per Share, Diluted, Other Disclosure [Abstract]
Aggregate number of common equivalent shares excluded from computations of diluted net loss per common share (in shares)	409,661		409,661

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2024 shares
Earnings Per Share [Abstract]
Common stock excluded from calculation of basic and diluted EPS	122,294

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent Event - Credit Agreement $ in Millions	Nov. 07, 2024 USD ($)
Subsequent Event [Line Items]
Debt aggregate amount	$ 50
Revenue covenants amount	$ 67.5